HR
NBIX icon

Howe & Rusling’s Neurocrine Biosciences NBIX Stock Holding History

Howe & Rusling’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10
Closed -$1K – 839
2019
Q4 		$1K Buy
+10
New +$1.05K ﹤0.01% 770
2016
Q3 		– Sell
-13
Closed -$1K – 1093
2016
Q2 		$1K Sell
13
-11
-46% -$506 ﹤0.01% 909
2016
Q1 		$1K Hold
24
– – ﹤0.01% 945
2015
Q4 		$1K Buy
24
+17
+243% +$864 ﹤0.01% 920
2015
Q3 		$0 Buy
+7
New +$338 ﹤0.01% 1055

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Howe & Rusling's NBIX Position: Q1 2020 in Review

Howe & Rusling sold out of Neurocrine Biosciences (NBIX) in Q1 2020, closing a stake of 10 shares — an estimated $1K sold.

Howe & Rusling first reported a position in NBIX in Q3 2015 and held it in 5 quarters. The position peaked at $1K in Q4 2019. 368 funds tracked by Wall St. Rank hold NBIX as of Q1 2020.

  • Howe & Rusling reported no remaining Neurocrine Biosciences position as of Q1 2020 after selling out during the quarter.
  • Howe & Rusling sold 10 Neurocrine Biosciences shares in Q1 2020, an estimated $1K.
  • Howe & Rusling first reported a position in Neurocrine Biosciences in Q3 2015 and held it in 5 quarters.
  • Howe & Rusling's Neurocrine Biosciences position peaked at $1K in Q4 2019.
  • 368 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2020.

Based on Howe & Rusling's 13F filing for Q1 2020, filed 14 May 2020.